INTRODUCTION

- Psoriasis (PsO) affects ~2–3% of adults in the US and ~4–5% of adults in Europe.6
- PsO can have a significant negative impact on the physical, emotional, psychosocial, and occupational well-being of affected patients, including patients' emotional state as well as their ability to work.5

Czornobay et al. (2017) http://www.plosone.org/article?id=10.1371/journal.pone.0170494

METHODS

Study Design

- CIMPACT: 48-week, phase 3, randomized, double-blind, placebo- and active-controlled trial. Patients were randomized 3:3:1:3 to CZP 400 mg every 2 weeks (Q2W), CZP 200 mg Q2W (after a loading dose of 400 mg at Weeks 0, 2, and 4), Placebo Q2W for 16 weeks or placebo Q2W for 12 weeks (Double-blind) or to LD CZP 200 mg Q2W (Open label) followed by CZP 400 mg every 2 weeks after 16 weeks.

Patients

- Patients were ≥18 years of age, had chronic plaque psoriasis (CSS≥15), and a history of treatment with ≥2 systemic treatments for ≥6 months in the prior 12 months

- Baseline disease characteristics: Mean ± SD

  - Mean age: 54 ±16 years
  - Mean sex: 59% male
  - Mean CSS: 23 ± 11
  - Mean disease duration: 16 ± 10 years
  - Mean body mass index: 26.9 ± 4.6
  - Mean scalp involvement: 22.1 ± 15.5
  - Mean intertriginous involvement: 22.1 ± 15.5
  - Mean joint involvement: 12.2 ± 27.6

- Baseline disease activity expressed as the Area Under the Curve (AUC) of PGA (0–100) (PGA-AUC) from Week 0 to Week 16 across 12 weeks of treatment: Mean ± SD

  - Mean PGA-AUC: 2889 ± 3232

Baseline to Week 16

- PASI 75 nonresponders entered an Escape Arm for 12 weeks of treatment with CZP 400 mg Q2W, CZP 200 mg Q2W, or PBO Q2W.

Baseline disease characteristics

- Baseline disease characteristics: Mean ± SD

  - Mean age: 54 ± 16 years
  - Mean sex: 59% male
  - Mean CSS: 23 ± 11
  - Mean disease duration: 16 ± 10 years
  - Mean body mass index: 26.9 ± 4.6
  - Mean scalp involvement: 22.1 ± 15.5
  - Mean intertriginous involvement: 22.1 ± 15.5
  - Mean joint involvement: 12.2 ± 27.6

- Baseline disease activity expressed as the Area Under the Curve (AUC) of PGA (0–100) (PGA-AUC) from Week 0 to Week 16 across 12 weeks of treatment: Mean ± SD

  - Mean PGA-AUC: 2889 ± 3232

Baseline to Week 16

- PASI 75 nonresponders entered an Escape Arm for 12 weeks of treatment with CZP 400 mg Q2W, CZP 200 mg Q2W, or PBO Q2W.

RESULTS

RESULTS

- Patient Disposition and Baseline Characteristics

  - A total of 85, 61, and 77 patients were randomized to CZP 400 mg Q2W, CZP 200 mg Q2W, or PBO, respectively (Figure 8).

- Patient demographics and baseline characteristics were similar between groups (Table 1).

Table 1. Patient demographics and baseline disease characteristics

- Domain improvement (%) responders at WPAI domain scores at Week 16


- Work productivity loss (overall work impairment)

  - Mean ± SD

    - Placebo: Mean ± SD: 27.8 ± 14.5
    - CZP 200 mg Q2W: Mean ± SD: 16.8 ± 10.9
    - CZP 400 mg Q2W: Mean ± SD: 12.3 ± 8.4

- Work productivity loss (overall work impairment)

  - Mean ± SD

    - Placebo: Mean ± SD: 27.8 ± 14.5
    - CZP 200 mg Q2W: Mean ± SD: 16.8 ± 10.9
    - CZP 400 mg Q2W: Mean ± SD: 12.3 ± 8.4

Figure 3. DLQI mean scores at baseline and Week 16

CONCLUSIONS

- Czornobay et al. (2017) http://www.plosone.org/article?id=10.1371/journal.pone.0170494

- Employees of Dermira, 36Week

- References


